| scholarly article | Q13442814 |
| P2093 | author name string | Byung Ik Kim | |
| Chong Il Sohn | |||
| Dong Il Park | |||
| Hong Joo Kim | |||
| Jung Ho Park | |||
| Woo Kyu Jeon | |||
| Yong Kyun Cho | |||
| Yoon Suk Jung | |||
| Kyu Yong Choi | |||
| Soo Kyung Park | |||
| Hyo Joon Yang | |||
| P2860 | cites work | EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 |
| Hepatitis B virus infection | Q73929492 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization | Q30853725 | ||
| Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 | ||
| Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level | Q34481474 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis | Q34615975 | ||
| Asian-Pacific consensus statement on the management of chronic hepatitis B: an update | Q35072182 | ||
| Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update | Q35706189 | ||
| Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus | Q37393925 | ||
| Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. | Q37394366 | ||
| Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. | Q43062879 | ||
| Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence | Q45394801 | ||
| Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. | Q45511057 | ||
| Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine | Q46552174 | ||
| Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. | Q46606214 | ||
| Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine | Q46749895 | ||
| Predicting cirrhosis risk based on the level of circulating hepatitis B viral load | Q46985831 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | adefovir | Q353551 |
| entecavir | Q418586 | ||
| lamivudine | Q422631 | ||
| P304 | page(s) | 350-358 | |
| P577 | publication date | 2016-09-25 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment | |
| P478 | volume | 22 |
Search more.